Let's examine the charts to see what traders can do now.
The charts and indicators of the drugstore giant are sending mixed signals, though its latest earnings report and guidance won't help its shares.
Here's what the charts of the pharmaceutical giant reveal.
The 'Big 3' pharmaceutical distributors stand to benefit from the aging U.S. population and raise their payouts each year.
With the major index ETFs starting to look a bit shaky, it might be best to watch from the sidelines for a bit.
These recently downgraded names are displaying both quantitative and technical deterioration.
The stock took off to the upside starting in late March.
Each of these names has seen favorable news around their pipelines.
Expect more weakness up ahead.
This will obviously be a huge market. It's time for me to diversify my exposure after positive news on Biogen and Eisai's Leqembi.